Fat LossMedium Risk
Retatrutide
Also known as: LY3437943
- Half-life:
- ~6 days
Administration Routes
subcutaneous injection
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Mechanism of Action
Triple GIP/GLP-1/glucagon receptor agonist; targets three pathways for synergistic fat reduction
A triple agonist peptide in clinical development showing exceptional weight loss results (up to 24% body weight). Targets GIP, GLP-1, and glucagon receptors simultaneously.
Primary Research Areas
- profound weight loss
- appetite suppression
- metabolic improvement
Risk Profile
Medium Risk
Moderate risk profile in research contexts. Consult a healthcare professional before use.
Regulatory Status
Research OnlyInvestigational
Triple GIP/GLP-1/glucagon agonist by Eli Lilly. Phase 3 TRIUMPH trials for obesity and T2D (NCT05929066). Phase 2 data published NEJM 2023. NDA submission expected 2026-2027.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.